Follow
Matts Kågedal
Matts Kågedal
Verified email at gene.com
Title
Cited by
Cited by
Year
Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity
M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ...
Pharmaceutical research 14, 176-180, 1997
641997
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region
M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ...
Neuroimage 82, 160-169, 2013
492013
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model
PH Zingmark, M Kågedal, MO Karlsson
Journal of pharmacokinetics and pharmacodynamics 32, 261-281, 2005
472005
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33, 75-91, 2006
412006
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde
International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013
362013
Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens
D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ...
CPT: Pharmacometrics & Systems Pharmacology 6 (6), 401-408, 2017
342017
Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study
WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ...
The Journal of Clinical Pharmacology 59 (5), 702-716, 2019
322019
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ...
Neuroimage 61 (4), 849-856, 2012
302012
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C …
K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ...
Psychopharmacology 213, 533-545, 2011
302011
Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study
A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ...
Drugs in R & D 6, 139-147, 2005
292005
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug …
MZ Liao, D Lu, M Kågedal, D Miles, D Samineni, SN Liu, C Li
Clinical Pharmacology & Therapeutics 110 (5), 1216-1230, 2021
282021
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
S Kawakatsu, R Bruno, M Kågedal, C Li, S Girish, A Joshi, B Wu
British Journal of Clinical Pharmacology 87 (6), 2493-2501, 2021
242021
True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers
M Kågedal, PH Zingmark, C Hedlund, R Yates
American Journal of Drug Delivery 3, 133-140, 2005
21*2005
PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ...
European Neuropsychopharmacology 18, S270-S270, 2008
202008
Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers
J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz
European Journal of Pain 17 (10), 1465-1471, 2013
152013
A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime.
M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ...
Journal of clinical pharmacology 47 (8), 1043-1049, 2007
152007
Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy
E Reyner, B Lum, J Jing, M Kagedal, JA Ware, LJ Dickmann
Clinical and Translational Science 13 (2), 410-418, 2020
132020
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li
Cancer Chemotherapy and Pharmacology 80, 1147-1159, 2017
132017
Early phase drug development for treatment of chronic pain—Options for clinical trial and program design
J Kalliomäki, F Miller, M Kågedal, R Karlsten
Contemporary clinical trials 33 (4), 689-699, 2012
122012
Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration
CC Wykoff, PA Campochiaro, DJ Pieramici, AM Khanani, S Gune, M Maia, ...
Ophthalmology and Therapy 11 (5), 1705-1717, 2022
112022
The system can't perform the operation now. Try again later.
Articles 1–20